European Union Chamber of Commerce in China
Pharma Working Group (Beijing & Shanghai)
Working Group Meeting
Date & Time: Tuesday 3rd Sept, 2013, 4pm (Beijing time)
Venues: 1) European Chamber Shanghai, Shui On Plaza, Unit 2204, 333 Huai Hai Zhong Road (near Madang Road), Shanghai
上海市淮海中路333号瑞安广场2204室 (近马当路)
2) European Chamber Beijing, Office C411A, Beijing Lufthansa Center, 50 Liangmaqiao Road, Chaoyang District, Beijing
北京市 朝阳区亮马桥路50号 燕莎中心写字楼 C-411A室
3) for people who could not attend at both venues, the Call-in Number is: 021- 6120 6622, Participation Code: *181938* (press * key before and after)
Please kindly register by directly replying to this email (pharma_sh@europeanchamber.com.cn) by COB 30 Aug 2013 indicating whether you will attend in Beijing or in Shanghai or with dial-in.
Dear Working Group member,
We are pleased to invite you for the upcoming Pharma Working Group meeting, which will take place on Tuesday 3 Sept 2013 from 4pm at the European Chamber offices in Shanghai and Beijing.
At this meeting we will have the great pleasure of welcoming:
1) Ms. Helen CHEN, from L.E.K. Consulting to give a presentation on ‘China’s Essential Drug List (EDL)’
Brief introduction of L.E.K.’s presentation:
The 2013 expansion of China’s Essential Drug List (EDL) from 307 to 520 drugs generated a flurry of news reporting and much chagrin in the boardrooms of multinational pharmaceutical companies. Chief amongst the anxieties are the new inclusions of more than a dozen multinational off-patent originator products (OPOs) amongst the list, and the requirement that Level 2 and 3 hospitals use a certain percentage of EDL drugs.
L.E.K. will share their recent analysis of the newly listed products, their historical and current pricing levels, the past four years of EDL experience and regulations, and the impact on EDL expansion on pricing and multinational pharma sales. In L.E.K.’s view, price declines and market access can be managed and continued growth is possible for these OPOs on the EDL list. The situation is navigable doesn’t necessarily mean a huge hit to the business that many feared.
2) European Federation of Pharmaceutical Industry Association (EFPIA) to present their latest key projects (via Tel-Conference) followed by discussion on collaboration with EUCCC members for lobby activities
Tentative Agenda
1) 16:00-16:10 Opening remark by the Chair
2) 16:10-16:45 Presentation by L.E.K. Consulting on EDL followed by discussion
3) 16:45-17:15 Presentation by EFPIA on the key projects followed by discussion
4) 17:15-17:30 break & Non-members are free to leave
5) 17:30-18:00 Closed meeting
a. Discussion about the final status of Position Paper (PP), Europe Tour, how best to combine the tour and fully utilize PP in the lobbying
b. Discussion about the upcoming lobby plan for the Working Group, identify next year PP issues
c. stakeholder mapping, potential members
6) Any other business
Short Bio of Ms. Helen CHEN: Helen Chen is a director and partner of L.E.K. Consulting, based in Shanghai. Helen is a member of L.E.K.’s Global Leadership Team, the firm’s executive committee. Helen has 25 years of consulting and industry experience in the US and Asia, and has resided in China since 2000. She is the head of L.E.K.’s China life sciences practice and leads medtech practice, with extensive case work and industry experience covering the full bio/pharmaceutical / medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness. She is on the Editorial Board of PharmAsia and is a frequent speaker and author on the opportunities and issues in the China healthcare and life sciences.
**************************************************************************************************************************************************************